



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 10-07 version)

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

### Complete if Known

|                        |                        |
|------------------------|------------------------|
| Application Number     | 10/590,690-Conf. #2874 |
| Filing Date            | August 25, 2006        |
| First Named Inventor   | Rosanne D. Dunn        |
| Art Unit               | Not Yet Assigned       |
| Examiner Name          | Not Yet Assigned       |
| Attorney Docket Number | 29729/38914            |

### U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| A1                 | US 4,458,066          | 07-03-1984  | Caruthers et al.               |  |   |
| A2                 | US 4,542,225          | 09-17-1985  | Blattler et al.                |  |   |
| A3                 | US 5,597,569          | 01-28-1997  | Siegall et al.                 |  |   |
| A4                 | US 6,075,181          | 06-13-2000  | Kucherlapati et al.            |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> -Number-Kind Code <sup>4</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>Or Relevant Figures Appear | T <sup>5</sup> |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| B1                 | EP 1342779            | 09-10-2003   | Fornix Biosciences NV          |  |   |                |
| B2                 | WO 1987/04462         | 07-30-1987   | Celltech Limited, et al.       |  |   |                |
| B3                 | WO 1989/06976         | 08-10-1989   | Quadrant Bioresources Limited  |  |   |                |
| B4                 | WO 1992/07075         | 04-30-1992   | The Wellcome Foundation Ltd.   |  |   |                |
| B5                 | WO 2003/004056        | 01-16-2003   | FB Rice & Co.                  |  |   |                |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IWF. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. <sup>1</sup>   | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-------------------|---|---|----------------|
| C1                | ABE et al., Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies, Am. J. Clin. Pathol., 100:67-74, 1993.   |   |                |
| C2                | ANDERSON et al., Management of multiple myeloma today, Semin. Hematol., 36:3-8, 1999.   |   |                |
| C3                | ARPIN et al., The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene Cμ-Cδ switch, and λ light chain expression, J. Exp. Med., 187:1169-1178, 1998.  |   |                |
| C4                | AVET-LOISEAU et al., Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation, Blood, 99:2185-2191, 2002. |   |                |
| C5                | BEAUCAGE et al., Deoxynucleoside phosphoramidites - a new class of key intermediates for deoxynucleotide synthesis, Tetrahedron Lett., 22:1859-1862, 1981.  |   |                |
| C6                | BENATTI et al., Nucleotide sequence of cDNA coding for saponin-6, a type-1 ribosome-inactivating protein from <i>Saponaria officinalis</i> , Eur. J. Biochem., 183:465-470, 1989.   |   |                |
| C7                | BERGSAGEL et al., In multiple myeloma, clonotypic B lymphocytes are detectable among CD19 <sup>+</sup> peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain, Blood, 85:436-447, 1995.                                   |   |                |
| C8                | BIRD et al., Single-chain antigen-binding proteins, Science, 242:423-426, 1988.   |   |                |
| C9                | BODEY et al., Genetically engineered monoclonal antibodies for direct antineoplastic treatment and cancer cell specific delivery of chemotherapeutic agents, Curr. Pharm. Des., 6:261-276, 2000.  |   |                |
| C10               | BOUX et al., A tumor-associated antigen specific for human kappa myeloma cells, J. Exp. Med., 148:1769-1774, 1983.  |   |                |

|                    |                    |                 |            |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Ronald Schwadron/ | Date Considered | 09/21/2008 |
|--------------------|--------------------|-----------------|------------|

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

|  |   |    |   |                        |                        |
|--|---|----|---|------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | Complete if Known      |                        |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | Application Number     | 10/590,690-Conf. #2874 |
|  |   |    |   | Filing Date            | August 25, 2006        |
|  |   |    |   | First Named Inventor   | Rosanne D. Dunn        |
|  |   |    |   | Art Unit               | Not Yet Assigned       |
|  |   |    |   | Examiner Name          | Not Yet Assigned       |
| Sheet  | 2 | of | 3 | Attorney Docket Number | 29729/38914            |

|     |   |  |  |  |  |
|-----|---|--|--|--|--|
| C11 | BRADWELL et al., Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine, Clin. Chem., 47:673-680, 2001.  |  |  |  |  |
| C12 | BRINKMANN et al., Independent domain folding of <i>Pseudomonas</i> exotoxin and single-chain immunotoxins: influence of interdomain connections, PNAS USA, 89:3075-3079, 1992.  |  |  |  |  |
| C13 | BUCHNER et al., A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies, Anal. Biochem., 205:263-270, 1992.       |  |  |  |  |
| C14 | CHOW et al., Isolation and DNA sequence of a gene encoding alpha-trichosanthin, a type I ribosome-inactivating protein, J. Biol. Chem., 265:8670-8674, 1990.  |  |  |  |  |
| C15 | CLARKE et al., Myeloid-specific gene expression, J. Leukoc. Biol., 63:153-168, 1998.  |  |  |  |  |
| C16 | COLCHER et al., Use of monoclonal antibodies as radiopharmaceuticals for the localization of human carcinoma xenografts in nude mice, Meth. Enzymol., 121:802-816, 1986.  |  |  |  |  |
| C17 | CÓRBI et al., CD11c integrin gene promoter activity during myeloid differentiation, Leuk. Lymph., 25:415-425, 1997.   |  |  |  |  |
| C18 | DALLA-FAVERA et al., BCL-6 and the molecular pathogenesis of B-cell lymphoma, Cold Spring Harb. Symp. Quant. Biol., 59:117-123, 1994.   |  |  |  |  |
| C19 | DAVIES et al., Novel therapeutic targets in multiple myeloma, Eur. J. Haematol., 64:359-367, 2000.  |  |  |  |  |
| C20 | DEBINSKI et al., A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and <i>Pseudomonas</i> exotoxin, J. Biol. Chem., 268:14065-14070, 1993. |  |  |  |  |
| C21 | DENARDO et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 lym-1 monoclonal antibody, Antibody Immunoncyl. Radiopharm., 1:17-33, 1988.   |  |  |  |  |
| C22 | DENARDO et al., Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies, Int. J. Biol. Markers, 2:49-53, 1987.   |  |  |  |  |
| C23 | DUNN et al., Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin, ImmunoTech., 2:229-240, 1996.   |  |  |  |  |
| C24 | European Search Report (Supplementary), EP 05706314, European Patent Office, 28 June 2007.  |  |  |  |  |
| C25 | FISHER et al., Role of PU.1 in hematopoiesis, Stem Cells, 16:25-37, 1998.   |  |  |  |  |
| C26 | FONSECA et al., Genetics and cytogenetics of multiple myeloma: a workshop report, Cancer Res., 64:1546-1558, 2004.  |  |  |  |  |
| C27 | HABUKA et al., Amino acid sequence of <i>Mirabilis</i> antiviral protein, total synthesis of its gene and expression in <i>Escherichia coli</i> , J. Biol. Chem., 264:6629-6637, 1989.                                |  |  |  |  |
| C28 | HALLEK et al., Multiple myeloma: increasing evidence for a multistep transformation process, Blood, 91:3-21, 1998.  |  |  |  |  |
| C29 | HAROUSEAU et al., The role of stem cell transplantation in multiple myeloma, Blood Rev., 16:245-253, 2002.  |  |  |  |  |
| C30 | HO et al., Cloning of the cDNA of alpha-momorcharin: a ribosome inactivating protein, Biochim. Biophys. Acta, 1088:311-314, 1991.   |  |  |  |  |
| C31 | HUSTON et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> , PNAS USA, 85:5879-5883, 1988.           |  |  |  |  |
| C32 | International Search Report, PCT/AU2005/000280, Australian Patent Office, 7 April 2005.   |  |  |  |  |
| C33 | ISLAM et al., Complete amino acid sequence of luffin-a, a ribosome-inactivating protein from the seeds of <i>Luffa cylindrica</i> , Agric. Biol. Chem., 54:1343-1345, 1990.   |  |  |  |  |
| C34 | KERHL et al., Molecular mechanisms regulating CD19, CD20 and CD22 gene expression, Immunol. Today, 15:432-436, 1994.  |  |  |  |  |
| C35 | KOVÁR et al., HPMMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia, J. Control. Release, 92:315-330, 2003.  |  |  |  |  |
| C36 | KREITMAN et al., Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with <i>Pseudomonas</i> exotoxin, Bioconjug. Chem., 4:581-585, 1993.  |  |  |  |  |
| C37 | KUNG et al., The complete amino acid sequence of antiviral protein from the seeds of pokeweed ( <i>Phytolacca americana</i> ), Agric. Biol. Chem., 54:3301-3318, 1990.  |  |  |  |  |

|                    |                    |                 |            |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Ronald Schwadron/ | Date Considered | 09/21/2008 |
|--------------------|--------------------|-----------------|------------|

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

|  |   |    |   |                        |                        |
|--|---|----|---|------------------------|------------------------|
| Substitute for form 1449/PTO   |   |    |   | Complete if Known      |                        |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | Application Number     | 10/590,690-Conf. #2874 |
|  |   |    |   | Filing Date            | August 25, 2006        |
|  |   |    |   | First Named Inventor   | Rosanne D. Dunn        |
|  |   |    |   | Art Unit               | Not Yet Assigned       |
|  |   |    |   | Examiner Name          | Not Yet Assigned       |
| Sheet  | 3 | of | 3 | Attorney Docket Number | 29729/38914            |

|     |  |  |
|-----|--|--|
| C38 | KYLE, Multiple myeloma: diagnostic challenges and standard therapy, Semin. Hematol., 38:11-14, 2001.   |  |
| C39 | KYLE, Update on the treatment of multiple myeloma, Oncologist, 6:119-124, 2001.  |  |
| C40 | LAUDER et al., Surface membrane phenotypic expression and treatment response of malignant lymphomas, J. Pathol., 145:259-268, 1985.  |  |
| C41 | NAGATA et al., Apoptosis mediated by the Fas system, Prog. Mol. Subcell. Biol., 16:87-103, 1996.   |  |
| C42 | NAKANO et al., ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies, J. Immunol. Meth., 275:9-17, 2003. |  |
| C43 | PASTAN et al., Immunotoxins, Cell, 47:641-648, 1986.   |  |
| C44 | RAMSAY et al., Bone marrow purging using monoclonal antibodies, J. Clin. Immunol., 8:81-88, 1988.  |  |
| C45 | RYOO et al., Novel therapies for multiple myeloma, Blood Rev., 16:167-174, 2002.   |  |
| C46 | SIEGALL et al., Functional analysis of domains II, Ib, and III of <i>Pseudomonas</i> exotoxin, J. Biol. Chem., 264:14256-14261, 1989.  |  |
| C47 | SORIA, Immunotoxins, ligand-toxin conjugates and molecular targeting, Pharmacol. Res., 21:35-46, 1989.   |  |
| C48 | SUN et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma, 5:517-520, 1986.  |  |
| C49 | THORPE et al., New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability <i>in vivo</i> , Cancer Res., 47:5924-5931, 1987.                        |  |
| C50 | TILLYER et al., Immuno-turbidimetric assay for estimating free light chains of Immunoglobulins in urine and serum, J. Clin. Pathol., 44:466-471, 1991.   |  |
| C51 | TORDSSON et al., Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma, Cancer Immunol. Immunother., 48:691-702, 2000.  |  |
| C52 | VITETTA et al., Redesigning nature's poisons to create anti-tumor reagents, Science, 238:1098-1104, 1987.  |  |
| C53 | WALDMANN, Monoclonal antibodies in diagnosis and therapy, Science, 252:1657-1662, 1991.  |  |
| C54 | WALKER et al., A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent, Adv. Exp. Med. Biol., 186:833-841, 1985.                      |  |
| C55 | WALKER et al., A rat model system for radioimmuno-detection of kappa myeloma antigen on malignant B cells, Eur. J. Nucl. Med., 12:461-467, 1986.   |  |
| C56 | Written Opinion of the International Searching Authority, PCT/AU2005/000280, Australian Patent Office, 7 April 2005.   |  |
| C57 | ZHAN et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, 99:1745-1757, 2002.                     |  |
| C58 | ZHANG et al., Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters, Cur. Topics Micro. Immunol., 211:137-147, 1996.                      |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                    |                    |                 |            |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Ronald Schwadron/ | Date Considered | 09/21/2008 |
|--------------------|--------------------|-----------------|------------|

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./